These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33374770)

  • 1. SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells.
    Jenke R; Holzhäuser-Rein M; Mueller-Wilke S; Lordick F; Aigner A; Büch T
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
    Bachleitner-Hofmann T; Sun MY; Chen CT; Tang L; Song L; Zeng Z; Shah M; Christensen JG; Rosen N; Solit DB; Weiser MR
    Mol Cancer Ther; 2008 Nov; 7(11):3499-508. PubMed ID: 18974395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SATB1 as oncogenic driver and potential therapeutic target in head & neck squamous cell carcinoma (HNSCC).
    Panchal O; Wichmann G; Grenman R; Eckhardt L; Kunz-Schughart LA; Franke H; Dietz A; Aigner A
    Sci Rep; 2020 May; 10(1):8615. PubMed ID: 32451408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks.
    Kataoka Y; Mukohara T; Tomioka H; Funakoshi Y; Kiyota N; Fujiwara Y; Yashiro M; Hirakawa K; Hirai M; Minami H
    Invest New Drugs; 2012 Aug; 30(4):1352-60. PubMed ID: 21655918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination Therapy.
    Gutsch D; Jenke R; Büch T; Aigner A
    Cells; 2021 Jan; 10(2):. PubMed ID: 33572976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Met-HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells.
    Stern YE; Al-Ghabkari A; Monast A; Fiset B; Aboualizadeh F; Yao Z; Stagljar I; Walsh LA; Duhamel S; Park M
    Cell Mol Life Sci; 2022 Mar; 79(3):178. PubMed ID: 35249128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Essential role of Her3 in two signaling transduction patterns: Her2/Her3 and MET/Her3 in proliferation of human gastric cancer.
    Yun C; Gang L; Rongmin G; Xu W; Xuezhi M; Huanqiu C
    Mol Carcinog; 2015 Dec; 54(12):1700-9. PubMed ID: 25400108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.
    Steinway SN; Dang H; You H; Rountree CB; Ding W
    PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway.
    Momeny M; Ghasemi R; Valenti G; Miranda M; Zekri A; Zarrinrad G; Javadikooshesh S; Yaghmaie M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Tumour Biol; 2016 Mar; 37(3):3913-23. PubMed ID: 26482609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer.
    Novoplansky O; Fury M; Prasad M; Yegodayev K; Zorea J; Cohen L; Pelossof R; Cohen L; Katabi N; Cecchi F; Joshua BZ; Popovtzer A; Baselga J; Scaltriti M; Elkabets M
    Int J Cancer; 2019 Aug; 145(3):748-762. PubMed ID: 30694565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-Phenybutyric acid promotes gastric cancer cell migration via histone deacetylase inhibition-mediated HER3/HER4 up-regulation.
    Shi X; Zheng C; Li C; Hou K; Wang X; Yang Z; Liu C; Liu Y; Che X; Qu X
    Cell Biol Int; 2018 Jan; 42(1):53-62. PubMed ID: 28851073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
    Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Kim J; Lee J; Kim C; Choi J; Kim A
    Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.
    Corso S; Ghiso E; Cepero V; Sierra JR; Migliore C; Bertotti A; Trusolino L; Comoglio PM; Giordano S
    Mol Cancer; 2010 May; 9():121. PubMed ID: 20500904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
    Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
    Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.
    Zhang Z; Wang J; Ji D; Wang C; Liu R; Wu Z; Liu L; Zhu D; Chang J; Geng R; Xiong L; Fang Q; Li J
    Clin Cancer Res; 2014 Sep; 20(17):4559-73. PubMed ID: 24973425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification.
    Okamoto W; Okamoto I; Arao T; Kuwata K; Hatashita E; Yamaguchi H; Sakai K; Yanagihara K; Nishio K; Nakagawa K
    Mol Cancer Ther; 2012 Jul; 11(7):1557-64. PubMed ID: 22729845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Src impairs the growth of met-addicted gastric tumors.
    Bertotti A; Bracco C; Girolami F; Torti D; Gastaldi S; Galimi F; Medico E; Elvin P; Comoglio PM; Trusolino L
    Clin Cancer Res; 2010 Aug; 16(15):3933-43. PubMed ID: 20628031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer.
    Lai AZ; Cory S; Zhao H; Gigoux M; Monast A; Guiot MC; Huang S; Tofigh A; Thompson C; Naujokas M; Marcus VA; Bertos N; Sehat B; Perera RM; Bell ES; Page BD; Gunning PT; Ferri LE; Hallett M; Park M
    Sci Signal; 2014 Apr; 7(322):ra38. PubMed ID: 24757178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation.
    Frazier NM; Brand T; Gordan JD; Grandis J; Jura N
    Oncogene; 2019 Mar; 38(11):1936-1950. PubMed ID: 30390071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.